Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
about
Anti-vascular endothelial growth factor for neovascular age-related macular degenerationIndividualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trialLutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis.Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.DNA sequence variants in PPARGC1A, a gene encoding a coactivator of the ω-3 LCPUFA sensing PPAR-RXR transcription complex, are associated with NV AMD and AMD-associated loci in genes of complement and VEGF signaling pathways.Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandlingComparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degenerationPreclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabThe chronic care for age-related macular degeneration study (CHARMED): study protocol for a randomized controlled trial.Quantitative Analysis of Segmented Fluorescein Angiography Images for the Follow-up of Choroidal Neovascular MembraneThe Chronic Care for Wet Age Related Macular Degeneration (CHARMED) Study: A Randomized Controlled Trial.Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes.Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration.Complement factor H and LOC387715/ARMS2/HTRA1 variant's frequencies and phenotypic associations in neovascular age-related macular degeneration, a pilot study.Switching from intravitreal ranibizumab to bevacizumab for age-related macular degeneration.Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.Genetic predictors of response to photodynamictherapy.Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review.Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting.Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration.Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration.
P2860
Q24194251-77124B90-6666-4DB3-9BB3-B46F135E9AAAQ26799492-AE01D7B3-4500-4B4A-A175-1C67F1EAB863Q28294611-9ED14620-8322-4421-B280-79EB5B2FFB0BQ34214289-035007B8-CE43-4C13-84C4-51CE6080F4CBQ34444212-1D32D1C2-C2C0-49BF-BE40-D7AAE959AF72Q34555655-DC6480AC-A0CD-4100-AC29-8D906E4DDB5BQ34645555-E0770E87-F8D4-4089-BCAB-E00D5662CA6EQ35060360-374E6285-B1E2-4691-AE69-0DA4FB421F1DQ35226694-0D6C2065-6408-4E4F-AF25-B0E21B2DFDBBQ35544126-43E6F0E7-97C2-4BE0-A904-E9FB0966ADAEQ35544176-33C9852A-B7D1-4340-8D03-4388B4525CBAQ35841740-95670965-0AF7-4D4B-84CC-346DD913D499Q36476651-5C2D33C6-9773-4FF1-B46C-AE173E1342ADQ36907322-B62E3C1E-4EA2-43F4-A1B5-F8DDFC7745A7Q36938286-213C8777-D995-4805-A70F-14758E1511F8Q37550855-89B259C2-E87A-44CC-A032-87D308D2736AQ37792817-CF4BA128-AE77-4E18-B35F-5AD7619ECDBBQ37931236-F1DA09FD-28F7-47E3-99E2-34B052F9C49DQ38127625-9DE811A5-5C6A-451B-A187-DE18FEBD20F7Q42268901-6B274796-F5FE-4807-82F6-29078EF0EEC7Q42770014-8BD265D8-AD83-4C8D-9E06-3A9719746160Q49176127-DE6BBD53-9F3F-4AA6-9427-E79F62539055Q55128789-BA5357A5-4A00-4A0F-B4E3-488EB89CC798Q55491304-34B7319B-03D7-4F29-8CA3-309E5CADEDCD
P2860
Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
name
Bevacizumab vs ranibizumab for ...... ed, randomized clinical trial.
@ast
Bevacizumab vs ranibizumab for ...... ed, randomized clinical trial.
@en
type
label
Bevacizumab vs ranibizumab for ...... ed, randomized clinical trial.
@ast
Bevacizumab vs ranibizumab for ...... ed, randomized clinical trial.
@en
prefLabel
Bevacizumab vs ranibizumab for ...... ed, randomized clinical trial.
@ast
Bevacizumab vs ranibizumab for ...... ed, randomized clinical trial.
@en
P2093
P50
P1476
Bevacizumab vs ranibizumab for ...... ed, randomized clinical trial.
@en
P2093
Antoun Houranieh
Ednan Ahmed
Edward Feinberg
Gelareh Abedi
Maileah Nguyen
Payal Patel
Sumit Bhatia
P304
P356
10.1016/J.AJO.2009.07.009
P407
P577
2009-10-02T00:00:00Z